TCRX logo

TScan Therapeutics, Inc. (TCRX)

Profile

Full Name

TScan Therapeutics, Inc.

Ticker Symbol

NASDAQ: TCRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

July 16, 2021

Indexes

Not included

Website

http://www.tscan.com

Employees

200

Key Details

Price

$1.51(+2.72%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$2.82M(-86.62% YoY)

Annual EPS

-$1.14(+16.18% YoY)

PE ratio

-

Next earnings date

Aug 12, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $1.51
    TCRX price is $1.51

    30-Day Relative Volume

    0.27
    TCRX 30-day relative volume is 0.27

    Price Performance

    Price Most recent change

    +2.72%
    TCRX price was up +2.72% on Jul 3, 2025

    Price YTD change

    -50.33%
    TCRX price is down -50.33% since January 1st

    Price 1-year change

    -74.23%
    TCRX price is down -74.23% year-on-year

    Price 3-year change

    -52.81%
    TCRX price is down -52.81% over the past 3 years

    Price Range

    Price All-time high

    $14.71
    TCRX price is currently -89.73% below its historical high of $14.71

    Price 3-year low

    $1.02
    TCRX price is currently +48.04% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market cap

    $85.45M
    TCRX market capitalization is $85.45 million

    Market cap 3-year change

    +10.93%
    TCRX market capitalization is up +10.93% over the past 3 years

    Market cap All-time high

    $493.21M
    TCRX market capitalization is currently -82.67% below its historical high of $493.21 million

    Market cap sector rank

    42.17%
    TCRX market capitalization is higher than 42.17% of companies in Healthcare sector

    Shares Outstanding

    Shares Outstanding 1-Year Change

    +6.91%
    TCRX shares outstanding is up +6.91% year-on-year

    Shares Outstanding 3-Year Change

    +135.08%
    TCRX shares outstanding is up +135.08% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    0.96
    TCRX beta is 0.96

    200-day SMA

    $2.86
    TCRX price is currently -47.20% below its 200-day simple moving average

    50-day SMA

    $1.49
    TCRX price is currently +1.02% above its 50-day simple moving average

    RSI

    50.24
    TCRX 14-day relative strength index is 50.24

    Volume

    0.27
    TCRX 30-day relative volume is 0.27

    ATR

    $0.12
    TCRX average true range is $0.12

    10-day Historical Volatility

    105.15%
    TCRX 10-day historical volatility is 105.15%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $2.82M
    TCRX annual revenue is $2.82 million

    Revenue Analysts estimate

    $5.88M
    TCRX annual revenue is currently -52.09% lower than the consensus analysts' forecast

    Revenue 1-year change

    -86.62%
    TCRX annual revenue is down -86.62% year-on-year

    Revenue Sector rank

    17.23%
    TCRX annual revenue is higher than 17.23% of companies in Healthcare sector

    EPS

    EPS

    -$1.14
    TCRX annual earnings per share is -$1.14

    EPS Analysts estimate

    -$1.23
    TCRX annual earnings per share is currently -7.67% lower than the consensus analysts' forecast

    EPS 1-year change

    +16.18%
    TCRX annual earnings per share is up +16.18% year-on-year

    EPS Sector rank

    53.22%
    TCRX annual earnings per share is higher than 53.22% of companies in Healthcare sector

    Profit

    Gross profit

    -
    TCRX annual gross profit value is unknown

    Gross margin

    -
    TCRX annual gross profit margin value is unknown

    Operating profit

    -$134.82M
    TCRX annual operating income is -$134.82 million

    Operating margin

    -4787.68%
    TCRX annual operating profit margin is -4787.68%

    Net income

    -$127.50M
    TCRX annual net profit is -$127.50 million

    Net margin

    -4527.66%
    TCRX annual net profit margin is -4527.66%

    Expenses

    Total expenses

    $137.64M
    TCRX annual total expenses is $137.64 million

    Operating expenses

    $137.64M
    TCRX annual total operating expenses is $137.64 million

    Cost of goods sold

    -
    TCRX annual cost of goods sold value is unknown

    Selling, general & administrative expenses

    $29.56M
    TCRX annual SGA is $29.56 million

    Depreciation and amortization

    $4.11M
    TCRX annual depreciation & amortization is $4.11 million

    Interest expense

    $3.65M
    TCRX annual interest expense is $3.65 million

    Income tax

    -
    TCRX annual income tax value is unknown

    EBIT & EBITDA

    EBIT

    -$123.85M
    TCRX annual earnings before interest & taxes is -$123.85 million

    EBITDA

    -$119.74M
    TCRX annual EBITDA is -$119.74 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total assets

    $371.12M
    TCRX annual total assets is $371.12 million

    Non current assets

    $78.40M
    TCRX annual long term assets is $78.40 million

    Current assets

    $292.72M
    TCRX annual total current assets is $292.72 million

    Cash and cash equivalents

    $178.69M
    TCRX annual cash & cash equivalents is $178.69 million

    Accounts receivable

    -
    TCRX annual accounts receivable value is unknown

    Inventory

    -
    TCRX annual inventory value is unknown

    Liabilities

    Total liabilities

    $130.15M
    TCRX annual total liabilities is $130.15 million

    Long term liabilities

    $94.19M
    TCRX annual total long term liabilities is $94.19 million

    Current liabilities

    $35.96M
    TCRX annual total current liabilities is $35.96 million

    Accounts payable

    $4.28M
    TCRX annual accounts payable is $4.28 million

    Debt

    Total debt

    $97.38M
    TCRX annual total debt is $97.38 million

    Total debt 1-year change

    +5.35%
    TCRX annual total debt is up +5.35% year-on-year

    Long term debt

    $92.81M
    TCRX annual long term debt is $92.81 million

    Short term debt

    $4.57M
    TCRX annual short term debt is $4.57 million

    Equity & Capital

    Shareholders equity

    $240.97M
    TCRX annual stockholders equity is $240.97 million

    Book value

    $240.97M
    TCRX annual book value is $240.97 million

    Retained earnings

    -$375.10M
    TCRX annual retained earnings is -$375.10 million

    Working capital

    $256.77M
    TCRX annual working capital is $256.77 million

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash from operations

    -$110.82M
    TCRX annual cash flow from operations is -$110.82 million

    Cash from operations 1-year change

    -80.62%
    TCRX annual cash flow from operations is down -80.62% year-on-year

    Cash from investing

    -$52.61M
    TCRX annual cash flow from investing activities is -$52.61 million

    Cash from investing 1-year change

    +13.41%
    TCRX annual cash flow from investing activities is up +13.41% year-on-year

    Cash from financing

    $208.76M
    TCRX annual cash flow from financing activities is $208.76 million

    Cash from financing 1-year change

    +54.13%
    TCRX annual cash flow from financing activities is up +54.13% year-on-year

    CAPEX

    CAPEX

    $3.83M
    TCRX annual capital expenditures is $3.83 million

    CAPEX 1-year change

    +21.58%
    TCRX annual capital expenditures is up +21.58% year-on-year

    Free Cash Flow

    Free cash flow

    -$114.65M
    TCRX annual free cash flow is -$114.65 million

    Free cash flow 1-year change

    -77.74%
    TCRX annual free cash flow is down -77.74% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross margin

    -
    TCRX annual gross profit margin value is unknown

    Operating margin

    -4787.68%
    TCRX annual operating profit margin is -4787.68%

    Net margin

    -4527.66%
    TCRX annual net profit margin is -4527.66%

    ROA & ROE

    ROA

    -39.64%
    TCRX annual return on assets is -39.64%

    ROE

    -65.08%
    TCRX annual return on equity is -65.08%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE ratio

    -
    TCRX price to earnings ratio value is unknown

    PE ratio Sector rank

    -
    TCRX price to earnings ratio is unknown

    PB Ratio

    PB ratio

    0.41
    TCRX price to book ratio is 0.41

    PB ratio Sector rank

    23.56%
    TCRX price to book ratio is higher than 23.56% of companies in Healthcare sector

    PS Ratio

    PS ratio

    19.33
    TCRX price to sales ratio is 19.33

    PS ratio Sector rank

    85.54%
    TCRX price to sales ratio is higher than 85.54% of companies in Healthcare sector

    Enterprise value

    Enterprise value

    $28.38M
    TCRX enterprise value is $28.38 million

    Enterprise value Sector rank

    31.93%
    TCRX enterprise value is higher than 31.93% of companies in Healthcare sector

    EV/EBITDA

    EV/EBITDA

    -0.23
    TCRX EV/EBITDA is -0.23

    EV/EBITDA Sector rank

    60.17%
    TCRX EV/EBITDA is higher than 60.17% of companies in Healthcare sector

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current ratio

    8.14
    TCRX annual current ratio is 8.14

    Quick ratio

    -
    TCRX annual quick ratio value is unknown

    Leverage

    Debt to equity

    0.13
    TCRX annual debt to equity ratio is 0.13

    Interest coverage ratio

    -33.90
    TCRX annual interest coverage ratio is -33.90

    Risk & Stability

    Piotroski F-Score

    -
    TCRX piotroski f-score value is unknown

    Altman Z-Score

    -1.28
    TCRX altman z-score is -1.28

    Analyst ratings

    Recent major analysts updates

    May 7, 25 HC Wainwright & Co.
    Buy
    Apr 8, 25 Needham
    Buy
    Mar 7, 25 Barclays
    Overweight
    Mar 6, 25 HC Wainwright & Co.
    Buy
    Mar 5, 25 Needham
    Buy
    Dec 11, 24 Needham
    Buy
    Dec 11, 24 HC Wainwright & Co.
    Buy
    Nov 15, 24 HC Wainwright & Co.
    Buy
    Nov 12, 24 Needham
    Buy
    Nov 6, 24 Needham
    Buy

    Institutional Ownership

    Screeners with TCRX included

    Growing Shares Outstanding
    US stocks
    Stocks below SMA 200
    Most recommended stocks
    Best performing stocks last 3 months
    NASDAQ Dividend Calendar
    Stocks below analysts price target
    Healthcare sector
    All stocks
    NASDAQ Listed Companies
    • What is the ticker symbol for TScan Therapeutics, Inc.?
    • Does TScan Therapeutics, Inc. pay dividends?
    • What sector is TScan Therapeutics, Inc. in?
    • What industry is TScan Therapeutics, Inc. in?
    • What country is TScan Therapeutics, Inc. based in?
    • When did TScan Therapeutics, Inc. go public?
    • Is TScan Therapeutics, Inc. in the S&P 500?
    • Is TScan Therapeutics, Inc. in the NASDAQ 100?
    • Is TScan Therapeutics, Inc. in the Dow Jones?
    • When was TScan Therapeutics, Inc.'s last earnings report?
    • When does TScan Therapeutics, Inc. report earnings?

    What is the ticker symbol for TScan Therapeutics, Inc.?

    The ticker symbol for TScan Therapeutics, Inc. is NASDAQ:TCRX

    Does TScan Therapeutics, Inc. pay dividends?

    No, TScan Therapeutics, Inc. does not pay dividends

    What sector is TScan Therapeutics, Inc. in?

    TScan Therapeutics, Inc. is in the Healthcare sector

    What industry is TScan Therapeutics, Inc. in?

    TScan Therapeutics, Inc. is in the Biotechnology industry

    What country is TScan Therapeutics, Inc. based in?

    TScan Therapeutics, Inc. is headquartered in United States

    When did TScan Therapeutics, Inc. go public?

    TScan Therapeutics, Inc.'s initial public offering (IPO) was on July 16, 2021

    Is TScan Therapeutics, Inc. in the S&P 500?

    No, TScan Therapeutics, Inc. is not included in the S&P 500 index

    Is TScan Therapeutics, Inc. in the NASDAQ 100?

    No, TScan Therapeutics, Inc. is not included in the NASDAQ 100 index

    Is TScan Therapeutics, Inc. in the Dow Jones?

    No, TScan Therapeutics, Inc. is not included in the Dow Jones index

    When was TScan Therapeutics, Inc.'s last earnings report?

    TScan Therapeutics, Inc.'s most recent earnings report was on May 6, 2025

    When does TScan Therapeutics, Inc. report earnings?

    The next expected earnings date for TScan Therapeutics, Inc. is August 12, 2025
    On this page